Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Hematology and Cell Therapy
Published in: Hematology and Cell Therapy 2/1997

01-04-1997 | Original article

Results of three courses of adriamycin, bleomycin, vindesine, and dacarbazine with subtotal nodal irradiation in 189 patients with nodal Hodgkin’s disease (stage I, II and IIIA)

Authors: M. André, P. Brice, D. Cazals, C. Hennequin, C. Fermé, Y. Kerneis, P. Rousselot, J. M. Zini, E. Lepage, C. Gisselbrecht

Published in: Hematology and Cell Therapy | Issue 2/1997

Login to get access
Metadata
Title
Results of three courses of adriamycin, bleomycin, vindesine, and dacarbazine with subtotal nodal irradiation in 189 patients with nodal Hodgkin’s disease (stage I, II and IIIA)
Authors
M. André
P. Brice
D. Cazals
C. Hennequin
C. Fermé
Y. Kerneis
P. Rousselot
J. M. Zini
E. Lepage
C. Gisselbrecht
Publication date
01-04-1997
Publisher
Springer Paris
Published in
Hematology and Cell Therapy / Issue 2/1997
Print ISSN: 1269-3286
Electronic ISSN: 1279-8509
DOI
https://doi.org/10.1007/s00282-997-0059-7

Other articles of this Issue 2/1997

Hematology and Cell Therapy 2/1997 Go to the issue

Review article

The ex vivo expansion capacity of normal human bone marrow cellsis dependent on experimental conditions: role of the cell concentration, serum and CD34+ cell selection in stroma-free cultures

6th Cell Therapy Workshop AMGEN-ROCHE

Thérapie génique du déficit immunitaire combiné sévère lié à LX

Case reports

Parvovirus B19 associated neutropenia. Treatment with Rh G-CSF

6th Cell Therapy Workshop AMGEN-ROCHE

Pathophysiology of Kostmann syndrome: the G-CSF receptor issue

6th Cell Therapy Workshop AMGEN-ROCHE

The use of cytokines in the treatment of solid tumours

Review article

Chronic myelomonocytic leukemia: from biology to therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits